問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Study Site

Study Site



Linkou Chang Gung Medical Foundation

  • 0

    Total Beds

  • 0

    Total Doctors

  • 244New Taipei CityLinkou

Recruiting Trial

916Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

2341Cases

2018-12-20 - 2030-01-31

Phase III

Active
A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

  • Condition/Disease

    Psoriatic Arthritis

  • Test Drug

    Risankizumab

Participate Sites
3Sites

Terminated3Sites

黃毓惠
Linkou Chang Gung Medical Foundation

2018-06-15 - 2021-06-30

Phase III

Completed
An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs. Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer(EV-301)

  • Condition/Disease

    Ureteral Cancer Urothelial Cancer Bladder Cancer

  • Test Drug

    Enfortumab Vedotin (ASG-22CE)

Participate Sites
6Sites

Recruiting6Sites

林永昌
Linkou Chang Gung Medical Foundation

2017-11-01 - 2020-03-19

Phase II/III

Completed
A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC)and Autologous Stem-Cell Transplantation (ASCT) – B-MIND

  • Condition/Disease

    Diffuse Large B-cell Lymphoma

  • Test Drug

    MOR00208

Participate Sites
11Sites

Not yet recruiting7Sites

Terminated3Sites

白禮源
China Medical University Hospital-Taipei

未分科

2018-08-01 - 2032-07-01

Phase III

Active
A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ALECTINIB VERSUS ADJUVANT PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB (TUMORS ≧ 4 CM) TO STAGE IIIA ANAPLASTIC LYMPHOMA KINASE-POSITIVE NON-SMALL CELL LUNG CANCER

  • Condition/Disease

    Carcinoma, Non-Small-Cell Lung

  • Test Drug

    RO5424802(Alectinib)、capsule、 150mg

Participate Sites
9Sites

Recruiting8Sites

2018-01-01 - 2023-05-12

Phase II/III

Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis

  • Condition/Disease

    Ulcerative Colitis (UC)

  • Test Drug

    Risankizumab

Participate Sites
6Sites

Recruiting6Sites

2026-03-19 - 2029-03-31

Others

Not yet recruiting
Multinational, Interventional, 52-week, Open-label, Single-arm Study to Evaluate the Treatment Outcomes of Anifrolumab 120 mg Subcutaneous Once Weekly in Immunosuppressant naïve and Biologic-naïve Systemic Lupus Erythematosus (SUNFLOWER)

  • Condition/Disease

    Systemic Lupus Erythematosus

  • Test Drug

    Anifrolumab (MEDI-546) 120 mg/0.8 mL (150mg/mL) accessorized Prefilled syringe

Participate Sites
1Sites

Recruiting1Sites

2018-06-01 - 2024-12-31

Phase III

Completed
A Phase III, Multiple-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of an Adjuvanted, Inactivated Enterovirus 71 (EV71) Vaccine in Healthy Infants and Children

  • Condition/Disease

    Enterovirus Infections

  • Test Drug

    "安拓伏"腸病毒71型疫苗

Participate Sites
8Sites

Terminated7Sites

2018-11-22 - 2021-10-26

Phase II

Completed
A Phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treated with imatinib and have not achieved deep molecular response

  • Condition/Disease

    CML Chronic Myelogenous Leukemia Leukemia, Myeloid Chronic Hematologic Diseases

  • Test Drug

    ABL001, GLIVEC (STI571), Tasigna (AMN107)

Participate Sites
3Sites

Recruiting3Sites

2017-08-28 - 2019-10-02

Phase III

Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin in subjects with type 2 diabetes A 30-week randomised, double-blind, double-dummy, active-controlled, parallel-group, multi-centre and multi-national trial

  • Condition/Disease

    Diabetes Diabetes Mellitus, Type 2

  • Test Drug

    Semaglutide

Participate Sites
3Sites

Terminated3Sites

陳涵栩
Taipei Veterans General Hospital

Division of Endocrinology

2018-06-01 - 2023-03-21

Phase III

Completed
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE

  • Condition/Disease

    Alzheimer Disease

  • Test Drug

    GANTENERUMAB

Participate Sites
8Sites

Terminated6Sites

劉景寬
Kaohsiung Municipal Gangshan Hospital

未分科

黃錦章
Linkou Chang Gung Medical Foundation

1 10 11 12 13 14 235
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB